Stewardship (Diagnostic and Antimicrobial) in Action: Individual Versus Data-driven Decision Making

Note: If you attended this live CE activity AND received CE/CME credit (i.e. a pharmacist CE statement of credit with ACPE UAN 0221-9999-21-020-L01-P, or a physician, nurse, laboratory professional or BCIDP statement of credit), you are NOT allowed to also receive credit for the home-study on-demand version of this activity.

A product of the Society of Infectious Diseases Pharmacists Education Center (SIDPEC) and the Center for Infectious Disease Research and Policy (CIDRAP) 

 View more SIDPEC Activities

Activity Description

This 1 hour and 15 minute accredited webinar will be presented by Dr. Brandon Bookstaver and Dr. Robin Patel along with moderator Dr. Marnie Peterson. Topics will include real-world examples of diagnostic stewardship and antimicrobial stewardship practices, the impact of diagnostic tools on antimicrobial stewardship programs, and strategies to resolve challengs and prevent silos to create interdisciplinary stewardship programs.

Target Audience

The target audience for this activity includes physicians, pharmacists, nurses, and clinical laboratory professionals.

Learning Objectives

At the completion of this activity, the participant will be better able to:

  • Describe real world examples of the integration of diagnostic stewardship and antimicrobial stewardship.
  • Use data to understand the impact of diagnostic stewardship on patient outcomes.
  • Implement interdisciplinary programs, avoiding disciplinary silos.


Robin Patel, MD
Elizabeth P. & Robert E. Allen Prof. of Individualized Medicine, Prof. of Medicine, Prof. of Microbiology
Mayo Clinic, Rochester, MN, USA

P. Brandon Bookstaver, PharmD, BCPS, FCCP, FIDSA
Associate Prof. & Dir. of Residency & Fellowship Training, Infectious Diseases Pharmacist
U. Of South Carolina, College of Pharmacy, Columbia, SC, USA

Marnie Peterson, PharmD, PhD
Outreach Coordinator, Antimicrobial Stewardship @Center for Infectious Disease Research & Policy
U. of Minnesota, USA

CME/CE Accreditation

Release Date: February 10, 2021
Expiration Date: February 10, 2022

ACPE Credit Designation (Pharmacist CE)

This activity is jointly provided by ProCE, LLC, CIDRAP (Center for Infectious Disease Research and Policy), and SIDP (Society of Infectious Diseases Pharmacists). ProCE is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-21-020-H01-P has been assigned to this home study knowledge-based activity. This CE activity is approved for 1.25 contact hours (0.125 CEU) in states that recognize ACPE providers. This CE activity is provided at no cost to participants. Completion of an evaluation and post-test with a score of 70% or higher is required to receive CE credit. Proof of completion will be posted in NABP CPE Monitor profiles. No partial credit will be given.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by ProCE, LLC and Clinical Care Options, LLC (CCO). Clinical Care Options, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.25 contact hours.

Clinical Laboratory Professionals CE

The Clinical and Laboratory Standards Institute is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E.® Program.


The Society of Infectious Diseases Pharmacists (SIDP) is accredited by the Board of Pharmacy Specialties (BPS) as a provider of board certified infectious diseases pharmacist (BCIDP) credit. A BCIDP statement of credit will be issued online upon successful completion of a post-test and online evaluation. The post-test must be successfully completed in only one attempt. No partial credit will be given. BCIDP accreditation begins 2/10/2021 for this activity and is available for one year from this date.

Recertification Criteria for Infectious Diseases Pharmacy: BCIDP recertifying via continuing education are required to earn 100 hours of continuing education credit provided by the joint program offered by the Society of Infectious Diseases Pharmacists (SIDP), the American College of Clinical Pharmacy (ACCP) and the American Society of Health-System Pharmacists (ASHP). Infectious Diseases Pharmacy Specialty Recertification Courses offered by any of the approved providers may only be completed for recertification credit up to two times, in nonconsecutive years, during the 7-year recertification cycle. Candidates should note that there are expiration dates associated with earning BPS recertification credit. BPS will only award recertification credit for modules based on the completion and submission date of the post-test assessment. For example, a module completed and submitted on October 20 of a particular year will only be credited for that year, even if the due date of the post-test is in January of the following year. View all recertification criteria on the BPS website at


It is the policy of ProCE, LLC to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants any significant financial interest or affiliation with companies that manufacture or market products discussed during their presentation.

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty and planners reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Marnie Peterson, PharmD, PhD has no relevant conflicts of interest to report.
Brandon Bookstaver, PharmD, FCCP, FIDSA, BCPS has disclosed that he has served as a Research advisor (contracted research) for and received consulting fees from Kedrion Biopharma.
Robin Patel, MD, D(ABMM), FIDSA, FACP, F(AAM) has disclosed that she has received funds for research support from ContraFect, Hylomorph, Shionogi, and TenNor Therapeutics Limited; and has received consulting fees from 1928 Diagnostics, Curetis, Next Gen Diagnostics, PathoQuest, and Specific Diagnostics (paid to her institution).
Kristine Moore, MD, MPH has no relevant conflicts of interest to report.
Maya Peters, MPH has no relevant conflicts of interest to report.
Catherine Harrison, RN, MPH has no relevant conflicts of interest to report.
CCO and ProCE Staff have no relevant conflicts of interest to report.

Potential conflicts of interest were resolved with a peer review process provided by Kristine Moore, MD, MPH.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


This CE activity is supported by an educational grant from BioMérieux.

The material presented in this CE activity does not reflect the views of ProCE, LLC or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.